Epidermal growth factor receptor-targeted therapy for pancreatic cancer.

Published

Conference Paper

Epidermal growth factor receptor (EGFR) plays an important role in tumor development and maintenance. It is a cell surface molecule that mediates signal transduction from the cell surface to cytoplasm. Elevated expression of EGFR or its ligand correlates with worse prognosis in a variety of human cancers. Therefore, blockade of EGFR activity would provide a novel strategy for the treatment of cancer. Two classes of EGFR inhibitors, monoclonal antibodies and tyrosine kinase inhibitors, have been described. The preclinical activity of these EGFR inhibitors and phase I clinical data are summarized in this article. A phase II trial of the EGFR inhibitor IMC-C225 in combination with gemcitabine for patients with advanced pancreatic cancer is discussed.

Full Text

Duke Authors

Cited Authors

  • Xiong, HQ; Abbruzzese, JL

Published Date

  • October 2002

Published In

Volume / Issue

  • 29 / 5 Suppl 14

Start / End Page

  • 31 - 37

PubMed ID

  • 12422311

Pubmed Central ID

  • 12422311

International Standard Serial Number (ISSN)

  • 0093-7754

Digital Object Identifier (DOI)

  • 10.1053/sonc.2002.35645

Conference Location

  • United States